VaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.
Hum Vaccin Immunother
; 10(10): 3022-38, 2014.
Article
em En
| MEDLINE
| ID: mdl-25483693
Palavras-chave
6MDP, 6-muramyl dipeptide; CGE, Capillary Gel Electrophoresis; CLO97, TLR7 ligand; CTL, Cytotoxic T-lymphocyte; CpG1826, Synthetic Oligodeoxynucleotide containing unmethylated dinucleotide sequences (Toll-like receptor 9 agonist); DARPA, Defense Advanced Research Projects Agency; EIDs, Emerging Infectious Diseases; Flu vaccine; GLP, Good Laboratory Practice; GMP, Good Manufacturing Practice; GP1, Glycoprotein-1; GP2, Glycoprotein-2; HLA, Human Leukocyte Antigen; HRP, Horseradish Peroxidase; LV, Lassa Fever Virus; Lassa fever virus; MAV, Mycobacterium tuberculosis Heat Shock Protein 70 Avidin; MtbHSP70, Mycobacterium tuberculosis Heat Shock Protein 70; NHP, Non-human Primates; OVA, Ovalbumin; PAGE, Polyacrylamide Gel Electrophoresis; PBMC, Peripheral Blood Mononuclear Cell; PEG, Polyethyleneglycol; RVKR, Furin Cleavage Site (Arginine, Valine, Lysine, Arginine); SAV, Self-assembled vaccine; SAVL; Self-assembled vaccine formulated for Lassa Fever Virus; VaxCelerate; arenavirus; emerging infectious diseases; mycobacterium tuberculosis heat shock protein 70; peptide design; self-assembled vaccine; vaccine
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Proteínas de Bactérias
/
Vacinas Virais
/
Avidina
/
Proteínas de Choque Térmico HSP70
/
Febre Lassa
Tipo de estudo:
Guideline
Limite:
Animals
Idioma:
En
Ano de publicação:
2014
Tipo de documento:
Article